Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy

By sjmartinez • September 19, 2024

Rovin BH, Ronco PM, Wetzels JFM, Adler SG, Ayoub I, Zaoui P, Han SH, Dudani JS, Gilbert HN, Patel UD, Manser PT, Jauch-Lembach J, Faulhaber N, Boxhammer R, Härtle S, Sprangers B. Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy. Kidney Int Rep. 2024 Jun 20;9(9):2635-2647. doi: 10.1016/j.ekir.2024.06.018. PMID: 39291206; PMCID: PMC11403052.

Tags: Clinical Trial, felzartamab, Harbor UCLA, MOR202, Nephrology, phase 2, phospholipase A2 receptor, primary membranous nephropathy, Publications

Regular Insulin Versus NPH Insulin for Continuous Enteral Tube Feeding in Hospitalized Patients

Kalangi ST, Bokka SM, Anand S, Garg R. Regular Insulin Versus NPH Insulin for Continuous Enteral Tube Feeding in Hospitalized Patients. Clin Diabetes. 2025 Apr[...]

Antiretroviral Therapy Intensification With Dolutegravir and/or Maraviroc Did Not Affect HIV-1 Cell-Associated DNA, RNA, and 2–LTR Circles Over 12 Weeks

Reed JC, Hall L, McKhann A, Kwak G, Goecker EA, Coombs RW, Chen H, Roa J, Vecchio A, Daar ES, Hunt PW, Marra CM, Campbell[...]

Lipoprotein(a), family history, and incidence of premature ASCVD events in a pooled US cohort

Fan Y, Fan W, Hu X, Tsai MY, Hoogeveen RC, Budoff MJ, Wong ND. Lipoprotein(a), family history, and incidence of premature ASCVD events in a[...]